594847-61-7

Upstream product

• 252000-90-1 methyl (3,4-di-O-tert-butyldimethylsilyl-D-glucuronate)glycal 
• 252000-95-6 methyl (3,4-di-O-tert-butyldimethylsilyl-2,3-anhydro)-D-glucuronate 
• 594847-59-3 (2S,3R,4R,5S,6S)-3,4,5-Tris-(tert-butyl-dimethyl-silanyloxy)-6-(3-hydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 594847-58-2 (2S,3R,4R,5S,6S)-6-Allyl-3,4,5-tris-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 594847-57-1 (2S,3R,4R,5S,6S)-6-Allyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 104004-96-8 (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-(methylamino)phenyl)-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one 
• 594847-60-6 (2S,3R,4R,5S,6S)-3,4,5-Tris-(tert-butyl-dimethyl-silanyloxy)-6-[3-(toluene-4-sulfonyloxy)-propyl]-tetrahydro-pyran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

An evaluation of a C-glucuronide as a liver targeting group: Conjugate of a glucocorticoid antagonist

A β-C-glucuronide conjugate of the glucocorticoid receptor antagonist, Mifepristone 1, was prepared which maintained binding affinity, had modest in vitro activity, and was metabolically more stable than the parent. Pharmacokinetic studies suggest that the conjugate is recognized by the liver like O-glucuronides and may undergo a portion of the enterohepatic recirculation loop.